The X-ray structure at 2.0-Å resolution of the p90 ribosomal S6 kinase 2 C-terminal kinase domain revealed a C-terminal autoinhibitory aL-helix that was embedded in the kinase scaffold and determines the inactive kinase conformation. We suggest a mechanism of activation through displacement of the aL-helix and rearrangement of the conserved residue Glu500, as well as the reorganization of the T-loop into the active conformation.
with a slightly more open cleft conformation than found in PKA.
Comparing the CTD and PKA invariant residues showed that Asp539 (RD-motif), Asn544 (catalytic loop) and Asp561 (DFG-motif), as well as the ionic pair between Glu463 (aC-helix) and Lys451 (b3-strand), essentially adopted the same conformation in both the CTD and PKA and fit the requirements for optimal phospho-transfer 13 . Despite extensive efforts to cocrystallize the protein with an unhydrolyzable ATP analog, we could not obtain ATP-bound crystals, suggesting that the CTD adopts an inactive conformation.
A notable difference between CTD RSK and active PKA entailed the position of the aD-helix, which was shifted by B5 Å from the cleft by the aL-helix N terminus (Fig. 2a) and an outward extrusion of the T-loop ( Fig. 1a and Supplementary Fig. 2a) . A subsequent comparison of CTD RSK2 with inactive Ca 2+ /calmodulin-dependent protein kinases, characterized by a twisted position of the N-terminal lobe and possession of C-terminal autoinhibitory helices that interfere with the binding site for ATP and substrate, illustrated their differences ( Fig. 2b and Supplementary Fig. 2b ). The aL-helix of CTD RSK2 in the 'cradle' did not occupy the catalytic cleft, and its autoinhibitory function is not obvious. However, inactive CTD and Table 1 online for details of the structure determination and crystallographic statistics, respectively. The sequence alignment is shown in Supplementary  Figure 4 online.
Ca 2+ /calmodulin-dependent protein kinases showed a similar shifted position of the aD-helix compared with active PKA. The noticeable shift of the CTD aD-helix was accompanied by spatial rearrangement of adjacent residues, including Glu500 (Fig. 2c) , which was turned away from the ATP binding site. The analogous residue Glu127 of PKA participates in hydrogen bonding to the ribose hydroxyl groups of ATP. Similar interactions were observed for glutamic or conserved aspartic acid residues in other kinase structures (Glu166 of phosphoinositide-dependent protein kinase-1 (PDB 1H1W), Glu236 of protein kinase B (PDB 1O6L), Glu100 of deathassociated protein kinase (PDB 1JKK), Asp100 of ERK2 (PDB 1GOL) and Asp86 of cyclin-dependent kinase-2 (PDB 1QMZ)). In addition, Glu127 of PKA also participates in the interaction with the positively charged arginine of the inhibitory peptide 14 . In the RSK2 CTD, Lys700 attracts and captures Glu500 (Fig. 2c) , forming an ionic pair (3.4 Å , 4.0 Å distances), and inhibits Glu500 from binding to ATP. This defines an autoinhibitory role of the aL-helix and reveals the structural basis for RSK2 activation. The CTD crystal structure suggests that disrupting the Tyr707-Ser603 hydrogen bond promotes displacement of the aL-helix and disruption of the Lys700-Glu500 ionic interaction, resulting in CTD activation, as demonstrated in vivo by truncation eliminating the aL-helix and by single Y707A mutation of RSK2 (ref. 9). We demonstrated that Xenopus embryos injected with mRNAs of the Y707A mutant showed severe defects of the anterior-posterior axis compared with wild type (Supplementary Fig. 3) .
The 'cradle' location of the aL-helix has two key consequences leading to the inactive kinase conformation: the displacement of the aD-helix, accompanied by misalignment of the active site residue Glu500 (Fig. 2a,c) , and the extrusion of the T-loop to an inactive conformation ( Fig. 1a and Supplementary Fig. 2a ). Unlike that of other kinase domains, the scaffold of the RSK2 CTD is stabilized by the aL-helix, which occupies the 'cradle' , rather than by the T-loop. On the basis of this structure of the CTD of RSK2, ERKs are likely to be involved in abolishing the autoinhibitory function of the CTD. The ERKs binding site (residues 726-735) is located at the RSK2 C terminus close to the aL-helix (residues 696-710). ERK docking to the C terminus should disrupt the Tyr707-Ser603 hydrogen bond and displace the aL-helix from its inhibitory position in the 'cradle' . The aL-helix displacement will release Glu500 from its ionic interaction with Lys700 and allow readjustment of the aD-helix position and proper alignment of Glu500 for ATP binding. The aL-helix displacement might also be associated with rearrangement of the phosphorylated T-loop and repositioning of it to the front of the catalytic cleft. Predictive conformational changes upon RSK2 CTD activation are similar to the autoinhibitory C-terminal aK-helix realignment in the homologous MAPK-activated protein kinase 2, as shown by X-ray crystallography of the constitutively active (PDB 1NXK) protein ( Supplementary Fig. 2c-e) .
Accession codes. Protein Data Bank: Coordinates and structure factors have been deposited with accession codes 2QR8 (native) and 2QR7 (selenomethionine). 
